Key facts
- Aba’s last known valuation is $10.5M (Jan 2023).
- It has raised $6.5M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Global Brain, SMBC Venture Capital, J-Startup, Spiral Capital (Tokyo), Sony Innovation Fund — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Aba
- ·The full record, as it builds
Funding rounds
No funding rounds for Aba are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aba
Developer of excretion care devices designed to help resolve the mental and physical burdens of caregivers and care recipients. The company offers a product that has a non-contact, non-invasive excretion sensor to detect excretion by smell and reduce replacement work during excretion and skin problems for long-term care recipients, enabling patients to receive better care efficiently.
- Sector
- Healthcare
- HQ
- Yachiyo, Japan
- Founded
- 2011
- Employees
- 50
- Website
- aba-lab.com/
- Ownership
- Privately Held (backing)
Aba doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aba shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aba in its N-PORT filings yet. We sweep new filings monthly.